PDL BioPharma acquires royalty, milestone rights from Depomed in $240.5M deal


PDL BioPharma (PDLI) acquires royalty and milestone rights on sales of Type 2 diabetes products licensed by Depomed (DEPO).

PDLI is paying $240.5M in cash and will receive all royalty and milestone payments up to $481M, after which time the two companies will split payments.

The rights acquired are tied to: Glumetza, Janumet XR, Invokana, among other products. (PR)

From other sites
Comments (1)
  • casenundra
    , contributor
    Comments (22) | Send Message
     
    And they said there was no life after Queen et al expired.
    22 Oct 2013, 11:53 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs